Meeting
2020 Gastrointestinal Cancers Symposium
A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.
Authors
Jeeyun Lee
Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea
Jeeyun Lee , Kerry Culm-Merdek , Jessicca Martin Rege , Andrew William Pippas , Johanna C. Bendell , Ian Chau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS459)
Abstract #
TPS459
Poster Bd #
L3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
First Author: Nikhil Shukla
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).
First Author: Farshid Dayyani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
First Author: Ilya Tsimafeyeu